About Biocon Biocon's Products & Services Research & Development Biocon's Technology Investors Media Careers CSR
  Press Releases
  Download Center
  Video Gallery
  Photo Gallery
  Media Contacts

Company Statement

Biocon´s Clarification post media reports on “Biocon on the FDA list for not paying facility fee”

Biocon has paid Facility Fee for its API facility to USFDA in Sep 2017

Bengaluru, Karnataka, India, Dec 13, 2017:

”This is in reference to certain media reports on Biocon being on the FDA list for non-payment of facility fee. We hereby clarify that Biocon's API facility has a different FEI no. for which the facility fee to the USFDA has been paid in September 2017. We are notifying the regulator on the inadvertent error of ascribing FEI no 3003981475 to our API facility and including it in the GDUFA facility fee arrear list. Biocon accords utmost importance to compliance and has not missed payment of any regulatory fee to the USFDA “


- Company Spokesperson

<< Back


 Download Company  Statement


Recommended sites Biocon on  
About Us

Investor Relations
Media Relations
Site Map
Contact Us
Our Growth Accelerators
Fact Sheet
Branded Formulations
Research Services
Active Discovery Program

Karnataka Vision Group on BT
Syngene International
Biocon Academy

    Linked In   
  Report adverse event/side effects and product complaints    
  * Disclaimer            © 2018, Biocon. All Rights Reserved